Study Comparing Low Doses of Olanzapine 2.5 mg vs 5 mg with Standard Medications to Prevent Nausea and Vomiting in Patients Receiving High-Dose Melphalan Chemotherapy for Multiple Myeloma
Led by Augusta University · Updated on 2024-11-22
172
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with multiple myeloma who receive high-dose melphalan chemotherapy before autologous stem cell transplantation. This trial aims to compare two lower doses of olanzapine 2.5 mg and 5 mg, given with three standard anti-nausea medications, to find which dose best prevents nausea and vomiting while causing the least sleepiness side effect. The study is randomized and double-blinded, focusing on chemotherapy-induced nausea, vomiting, and sedation outcomes.
Participants will be randomly assigned to receive either 2.5 mg or 5 mg of olanzapine on the day they receive high-dose melphalan and for three days afterward. Both groups will continue to receive the standard three medications routinely used to prevent nausea and vomiting. The study compares these two olanzapine doses as part of quadruplet antiemetic prophylaxis.
During the study, participants will be monitored from the day of chemotherapy through five days after for nausea, vomiting, sedation, and the need for additional antiemetic medications. Researchers will use measures such as complete response to nauseavomiting, protection from nausea, number of vomiting episodes, and sedation levels. The trial includes assessments of these effects to determine the best olanzapine dose. The entire participation period covers the acute and delayed phases of chemotherapy side effects.
CONDITIONS
Brief Title
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Research Team
A
Amber Clemmons, PharmD, BCOP, FHOPA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Olanzapine 2.5 mg with ondansetron, dexamethasone, and NK1-antagonist
Olanzapine 5 mg with ondansetron, dexamethasone, and NK1-antagonist
What is it?
Lower-dose olanzapine (2.5 mg) combined with ondansetron, dexamethasone, and a neurokinin-1 antagonist, given as prophylaxis against nausea and vomiting following high-dose melphalan in autologous stem cell transplantation.
Standard-dose olanzapine (5 mg) combined with ondansetron, dexamethasone, and a neurokinin-1 antagonist, used as antiemetic prophylaxis following high-dose melphalan in autologous stem cell transplantation.
Role in trial
Investigational dose used to evaluate whether 2.5 mg olanzapine provides non-inferior protection from chemotherapy-induced nausea and vomiting compared to 5 mg.
Active comparator dose, considered the standard within quadruplet antiemetic regimens for highly emetogenic chemotherapy in this setting.
Primary use
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (high-dose melphalan) in multiple myeloma transplant patients.
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (high-dose melphalan) in multiple myeloma transplant patients.
How it is given
Olanzapine 2.5 mg is administered orally alongside ondansetron, dexamethasone, and a neurokinin-1 antagonist, starting prior to high-dose melphalan and continuing across acute and delayed phases post-chemotherapy.
Olanzapine 5 mg is administered orally with ondansetron, dexamethasone, and a neurokinin-1 antagonist before high-dose melphalan, continued through the acute and delayed post-chemotherapy phases.
Evidence status
Emerging evidence including randomized trials in solid tumor settings shows that low-dose olanzapine (2.5 mg) is non-inferior to standard-dose for preventing nausea and vomiting during highly emetogenic chemotherapy, with potentially reduced sedation, but evidence in stem cell transplantation recipients is still limited.
Established randomized evidence supports 5 mg olanzapine as a component of quadruplet antiemetic prophylaxis, showing strong efficacy for nausea/vomiting prevention with accepted tolerability in hematologic transplantation settings.
Important limitations
The non-inferiority and lower-sedation findings for 2.5 mg olanzapine are based on solid tumors; limited data address performance in stem cell transplant populations, and this dose’s long-term impact in the studied context remains under evaluation.
While efficacy for 5 mg olanzapine is well demonstrated, higher doses are associated with increased sedation risk. This dose’s safety profile in vulnerable stem cell transplant recipients requires careful monitoring and confirmation in new studies.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Receipt of high-dose melphalan 140-200 mg/m2
Autologous stem cell transplantation recipient
You will not qualify if you...
Allergy to olanzapine
Documented nausea or vomiting within 24 hours prior to enrollment
Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy
Chronic alcoholism
Pregnant
Decline or unable to provide informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 5 days
Participants receive olanzapine 2.5 mg or 5 mg along with standard antiemetic prophylaxis starting on the day of high-dose melphalan chemotherapy and continuing for three days after to prevent nausea and vomiting.
Daily visits or assessments during chemotherapy and the following 4 days
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Evaluating 18F-Fluciclovine PETCT Imaging for Multiple Myeloma Detection and Monitoring
Evaluating 68Ga-BCMA PETCT Imaging for Detecting BCMA in Multiple Myeloma Patients in a Multicenter Study
Italian National Registry to Monitor Diagnosis and Treatment of Multiple Myeloma
A Physician and Patient-Powered Cohort Study
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1 Study of Subcutaneous TQB2934 Injection for Treating Malignant Plasma Cell Tumors Including Multiple Myeloma
Study of Allogeneic CD19 and BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B-cell or Plasma Cell Tumors
Early Phase 1 Trial to Assess Safety and Effectiveness of RN1101 Treatment
Phase I Open-Label Study of SHR-5421 Injection Evaluating Safety and Preliminary Effects in Patients With Multiple Myeloma
Phase I Study of SHR-9539 Injection to Evaluate Safety and Effectiveness in Adults With Multiple Myeloma
Phase 1 Study of TQB2029 Injection to Test Safety and Effects in Adults With Multiple Myeloma
Evaluating Safety and Effectiveness of LVIVO-TaVec200 in Adults with Relapsed or Refractory Multiple Myeloma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Amber B Clemmons, Julianne Orr, Benjamin Andrick...
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.